Results 161 to 170 of about 4,064 (194)

Comparison of QuantiFERON-TB Gold Plus, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB among patients with tuberculosis

Journal of Infection and Chemotherapy, 2020
This study evaluated the efficacy of the following interferon (IFN)-γ release assays (IGRAs): QuantiFERON-TB Gold Plus (QFT-Plus), QFT-Gold In-Tube (QFT-GIT), and T-SPOT. TB (T-SPOT) with the quantitative values of IFN-γ response.Blood samples were collected from patients with active tuberculosis (TB), latent TB infection (LTBI), individuals with ...
Keita Takeda, Maho Suzukawa
exaly   +3 more sources

Repeatability of QuantiFERON-TB gold plus testing utilizing microparticle chemiluminescence

Journal of Immunological Methods, 2022
Detection of latent Mycobacterium tuberculosis (LTBI) in patients is important to prevent active infection and the spread of disease, particularly in vulnerable patient populations. In 2020, a kit on the high throughput Liaison XL (DiaSorin) became commercially available for the analysis of QuantiFERON-TB Gold Plus assay (Qiagen).
Caleb, Cornaby   +2 more
openaire   +2 more sources

Comparison of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube tests for patients with active and latent tuberculosis: A prospective cohort study

Journal of Infection and Chemotherapy, 2021
We aimed to determine the diagnostic performance and clinical value of the QuantiFERON-TB Gold In-Tube (QFT-GIT) and QuantiFERON-TB Gold Plus (QFT-Plus) tests in patients with active tuberculosis (TB) or latent TB infection (LTBI).We prospectively enrolled 140 patients, including 63 with active TB and 77 with LTBI, between March 2017 and October 2018 ...
Jung-Kyu Lee   +2 more
exaly   +3 more sources

Comparison of the accuracy of QuantiFERON TB gold in tube vs QuantiFERON-TB plus

10.2 Tuberculosis, 2016
INTRODUCTION: Among the IFN-g release assays (IGRA), QuantiFERON-TB Plus (QFT-Plus) is a new generation of QuantiFERON TB Gold In tube (QFT-IT) which includes an additional antigen tube (TB2). The TB1 tube contains ESAT-6 and CFP-10 derived peptides (TB-7.7, present in QFT-GIT, has been removed), designed to induce a specific response from CD4+T-cells.
Valentina Vanini   +7 more
openaire   +1 more source

Comparative evaluation of CLIA and EIA for Quantiferon‐TB Gold Plus

APMIS, 2020
The purpose of this study was to compare the Quantiferon‐TB Gold Plus test analysed with chemiluminescence immunoassay (CLIA) to immunoassay (EIA). One hundred and twenty‐five clinical specimens submitted to Karolinska University Hospital for Quantiferon‐TB Gold Plus analysis were used to analyse agreement of the CLIA and EIA assays. The imprecision on
Sandra, Brantestig   +5 more
openaire   +2 more sources

Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon-γ release assays: A systematic review and meta-analysis

Advances in Medical Sciences, 2019
QuantiFERON-TB Gold Plus (QFT-Plus) is a new generation of QuantiFERON assay that differs from QuantiFERON-TB Gold In-Tube test (QFT-GIT). The aim of this study was to compare the performance of the new FDA-approved QFT-Plus interferon (IFN)-γ release assays (IGRAs) with the QFT-GIT version of this assay.We searched all studies published in English in ...
Setareh Mamishi, Shima Mahmoudi
exaly   +3 more sources

[Comparison of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In Tube in the diagnosis of pulmonary tuberculosis].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2022
Objective: To compare the screening value of QuantiFERON-TB Gold Plus (QFT-Plus) and QuantiFERON®-TB Gold in tube (QFT-GIT) in the auxiliary diagnosis of pulmonary tuberculosis (TB). Methods: A screening test was performed. Patients who were hospitalized in Guangzhou Chest Hospital and underwent QFT-GIT testing from October to December 2020 were ...
X Y, Wang   +6 more
openaire   +1 more source

Evaluation of treatment response in active tuberculosis using QuantiFERON-TB Gold Plus

European Cytokine Network, 2020
Tuberculosis (TB) is one of the leading infectious causes of death worldwide and despite the progress recently made in TB control at a global level, the decline in its incidence is still slow. It is therefore crucial to evaluate the performance of new tools for monitoring of TB treatment.
Setareh, Mamishi   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy